Modulation of either mtROS production or HIF-1α activity in cART-treated HIV-1-infected individuals could represent a therapeutic strategy to counterbalance inflammation during HIV-1 infection, thus reducing the risk of developing serious non-AIDS events. Here, HIF1A is linked to HIV-1 infection.